For The Better

The neuroscience-focused biotech company didn’t give investors the result they wanted.

Here’s what many investors missed during this biotech stock’s recent run-up.

Efficacy against variants is showing the drug is the gold standard in preventing COVID.

These recent additions to Berkshire Hathaway’s portfolio all pay at least a 4.4% yield.

This spacial data company looks promising. Should investors take a closer look before it’s officially a public company?

One word: leverage.

These blazing-hot deals won’t last for long.

The news continued to be good for mRNA vaccines.

Analysts view all three as rebound candidates.

You don’t need your ex’s permission to capitalize on this benefit-boosting trick.

Coronavirus players may deliver strong returns well into the future.

Every double-digit decline throughout history has proved to be a buying opportunity.

You can cut out the guesswork by investing in these three top growth stocks.

Play your cards right during your 50s, and you’ll set the stage for higher benefits later in life.

Social Security payments could climb significantly this year because of inflation.

There was a big shakeup in the biotech’s C-suite.

The company announced the pricing on an issuance of common stock.

Investors reacted negatively to the company’s warrant exchange.

The meme stock traders strike again today.

Earnings from the firearms maker surpassed estimates, and the company is rewarding shareholders.